Episode 9: How Novo Nordisk and UNC Health are using N3C resources to accelerate research on COVID-19 and metabolic disease

By |2020-11-23T11:33:33-04:00November 10th, 2020|

In this podcast Novo Nordisk researcher Dr. Kajsa Kvist and Dr. John Buse from the University of North Carolina at Chapel Hill (UNC Health) discuss how and why Novo Nordisk became an early participant of the National COVID-19 Collaborative (N3C), as a tool to study the pandemic. The Novo Nordisk patient analytics team led by Dr. Kvist is studying how COVID-19 affects patients with diabetes to learn how their products can help infected patients. The collaborators discuss the working model they established to leverage the strengths of academic and industry partners through the N3C. [Read more]

Episode 7: Scope of Real-world Data in Clinical Trials

By |2020-11-03T09:02:11-04:00October 28th, 2020|

In this podcast, Dan Housman and Craig Lipset discuss innovative and alternative approaches where Real World Data approaches are becoming increasingly integrated into clinical trials. They explore the increasing opportunity to electronically source real world data for clinical trials including integrating patient voices into consent and feedback of results. Craig shares a vision of how these new approaches can enable improvements that can lead to both better patient satisfaction and more efficient clinical research as a result. [Read more]

Episode 6: Scope of Real-world Data in Drug Repositioning

By |2020-11-09T18:28:18-04:00October 20th, 2020|

The N3C provides a unique resource for commercial organizations seeking to execute COVID-19 related research. In this podcast Dan Housman interviewed Joy Alamgir from ARI Science, an early adopter from a commercial research group having executed one of the first approved Data Use Requests. The conversation explores their decision to use N3C as a platform to study the real world performance of marketed drugs they have identified for repurposing for COVID-19. Joy provides insight into how his team learned about N3C, alternatives his team considered, the key benefits to his group, and ARI Science's early experience working with the enclave and data sets.[Read more]

Episode 5: In the Mood for Data

By |2020-11-09T16:16:06-04:00October 15th, 2020|

In this podcast, Dan Housman and Giuliana Kotikela, Co-Founder and CEO of ChiKeey, a fashionable and functional wearable device discuss the utility of real-time biometrics and advanced real-world data and analytics to assess and analyze emotional wellness. Chikeey’s solution utilizes unique indicators to proactively identify potentially significant changes in mental health where individuals may benefit from earlier intervention either via support or therapies. With this perspective we will discuss future applications to support the next generation of clinical research and patient care via remote monitoring. [Read more]

Episode 4: Insights from N3C : New RWD Initiative

By |2020-11-09T16:20:28-04:00September 9th, 2020|

In this podcast, Melissa Haendel, Director at CD2H and Christopher Chute Co-Director at CD2H discuss the key goals of the N3C initiative and its unique value proposition. The podcast provides insights into how this collaborative effort brings together experts with knowledge, skills, and experience to address this urgent public health issue. The podcast outlines the scope, opportunities, and challenges of N3C association with the commercial groups such as pharma & med-devices. It also touches upon the various roadblocks faced by the team in their journey so far. [Read more]

Episode 3: The Next Generation of Establishing Therapeutic Value

By |2020-11-09T16:15:00-04:00September 3rd, 2020|

Advanced real-world data including clinical notes, imaging, consumer data, and remote monitoring are redefining therapeutic value in modern reimbursement and prescribing dialogs. In the latest episode of Graticule’s Novel Cohorts Podcast Ömer Saka, Real-World Evidence Leader at PwC Switzerland and Dan Housman, CTO & Co- founder at Graticule, Inc. explore the emergence of a new generation of therapeutic value research. [Read more]